News Releases

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
10/17/2017
7:30 AM ET
Press Release

Diffusion Pharmaceuticals Receives Final FDA Protocol Guidance for Phase 3 Clinical Trial with TSC in Patients Newly Diagnosed with Inoperable Glioblastoma Multiforme

10/17/2017

CHARLOTTESVILLE, Va., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc.(NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the li...

 Continue Reading
10/10/2017
10:00 AM ET
Press Release

Diffusion Pharmaceuticals to Present at the 2017 BIO Investor Forum

10/10/2017

CHARLOTTESVILLE, Va., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc.(NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on the development...

 Continue Reading
9/5/2017
11:11 AM ET
Press Release

Diffusion Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

9/5/2017

CHARLOTTESVILLE, Va., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc.(NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on the development...

 Continue Reading
8/23/2017
7:30 AM ET
Press Release

Diffusion Pharmaceuticals Names William Hornung Chief Business Officer

8/23/2017

CHARLOTTESVILLE, Va., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc.(NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on the development...

 Continue Reading
8/14/2017
4:01 PM ET
Press Release

Diffusion Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

8/14/2017

CHARLOTTESVILLE, Va., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc.(NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on the development...

 Continue Reading
7/31/2017
8:30 AM ET
Press Release

Diffusion Pharmaceuticals Selects Contract Research Organization for Phase 3 Clinical Trial of Lead Compound TSC for Inoperable GBM Brain Cancer

7/31/2017

CHARLOTTESVILLE, Va., July 31, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN), a clinical stage biotechnology company developing novel small molecule therapeutics for cancer...

 Continue Reading
7/20/2017
8:30 AM ET
Press Release

Diffusion Pharmaceuticals Achieves Drug Production Milestone For Planned Phase 3 Clinical Trial In Inoperable GBM Brain Cancer

7/20/2017

CHARLOTTESVILLE, Va., July 20, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a clinical stage biotechnology company developing novel small molecule therapeutics for cancer a...

 Continue Reading
Displaying 1 to 7 (of 83 releases)